Abstract:BACKGROUND O-6-methylguanine-DNA methyltransferase (MGMT) is a suicide enzyme that repairs the mispairing base O-6-methyl-guanine induced by environmental and experimental carcinogens. It can transfer the alkyl group to a cysteine residue in its active site and became inactive. The chemical carcinogen N-nitroso compounds (NOCs) can directly bind to the DNA and induce the O-6-methylguanine adducts, which is an important cause of gene mutation and tumorigenesis. However, the underlying regulatory mechanism of MGMT involved in NOCs-induced tumorigenesis, especially in the initiation phase, remains largely unclear. AIM To investigate the molecular regulatory mechanism of MGMT in NOCs-induced gastric cell malignant transformation and tumorigenesis. METHODS We established a gastric epithelial cell malignant transformation model induced by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) or N-methyl-N-nitroso-urea (MNU) treatment. Cell proliferation, colony formation, soft agar, cell migration, and xenograft assays were used to verify the malignant phenotype. By using quantitative real-time polymerase chain reaction (qPCR) and Western blot analysis, we detected the MGMT expression in malignant transformed cells. We also confirmed the MGMT expression in early stage gastric tumor tissues by qPCR and immunohistochemistry. MGMT gene promoter DNA methylation level was analyzed by methylation-specific PCR and bisulfite sequencing PCR. The role of MGMT in cell malignant transformation was analyzed by colony formation and soft agar assays. RESULTS We observed a constant increase in MGMT mRNA and protein expression in gastric epithelial cell malignant transformation induced by MNNG or MNU treatment. Moreover, we found a reduction of MGMT gene promoter methylation level by methylation-specific PCR and bisulfite sequencing PCR in MNNG/MNU-treated cells. Inhibition of the MGMT expression by O-6-benzylguanine promoted the MNNG/MNU-induced malignant phenotypes. Overexpression of MGMT partially reversed the cell malignant transformation process induced by MNNG/MNU. Clinical gastric tissue analysis showed that MGMT was upregulated in the precancerous lesions and metaplasia tissues, but downregulated in the gastric cancer tissues. CONCLUSION Our finding indicated that MGMT upregulation is induced via its DNA promoter hypomethylation. The highly expressed MGMT prevents the NOCs-induced cell malignant transformation and tumorigenesis, which suggests a potential novel approach for chemical carcinogenesis intervention by regulating aberrant epigenetic mechanisms.

Promoter Hypermethylation of DNA Repair Gene O~6- methylguanine DNA Methyltransferase in Gliomas

O6-methylguanine DNA Methyltransferase is Upregulated in Malignant Transformation of Gastric Epithelial Cells Via Its Gene Promoter DNA Hypomethylation

O-6-Methylguanine-Dna Methyltransferase (Mgmt): Challenges And New Opportunities In Glioma Chemotherapy

Post-Transcriptional Regulation of O-6-Methylguanine-Dna Methyltransferase Mgmt in Glioblastomas

O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy

MGMT gene promoter methylation in malignant melanoma patients

The Clinical Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis

The Correlation between Aberrant Promoter Methylation of MGMT and Immunohistochemical Expression with Clinical Prognosis in Glioblastoma Multiforme

Direct, Real-Time PCR (methylight) Assay for Methylation of O6-methylguanine-DNA Methyltransferase Promoter in Glioma.

Methylation of O6-methylguanine DNA Methyltransferase Promoter is a Predictive Biomarker in Chinese Melanoma Patients Treated with Alkylating Agents

Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBM.

Changes of O6-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse—A Meta-Analysis Type Literature Review

Discriminating MGMT Promoter Methylation Status in Patients with Glioblastoma Employing Amide Proton Transfer-Weighted MRI Metrics

Methylation Status of Promoter 1 Region of GDNF Gene in Human Glioma Cells.

Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review)

The prognostic value of MGMT promoter methylation in glioblastoma: A meta‐analysis of clinical trials

Glioblastoma with high O6-methyl-guanine DNA methyltransferase expression are more immunologically active than tumors with low MGMT expression

Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma

Hypermethylation of the RASSF1A gene in gliomas.

A systematic review of high impact CpG sites and regions for MGMT methylation in glioblastoma

Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients